- US-listed companies
- FATE THERAPEUTICS INC
- Income statement
FATE THERAPEUTICS INC (FATE) Income statement
Market cap
$135.27M
P/E ratio
| 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 5 | - | 2 | - | - | 5 | 11 | 31 | 56 | 96 | 64 | 14 |
| Revenue growth (%) | - | - | - | - | - | - | ||||||
| Research & development | 57 | 16 | 20 | 26 | 34 | 56 | 88 | 126 | 216 | 320 | 173 | 135 |
| Operating margin (%) | - | - | - | |||||||||
| Operating expenses | 88 | 25 | 30 | 36 | 46 | 72 | 111 | 160 | 273 | 405 | 254 | 224 |
| Operating income | -18 | -25 | -28 | -32 | -42 | -67 | -101 | -128 | -217 | -308 | -191 | -210 |
| Net income | -21 | -26 | -30 | -33 | -43 | -67 | -98 | -173 | -212 | -282 | -161 | -186 |
| Net income margin (%) | - | - | - | |||||||||
| Earnings per share | - | - | - | - | - | - | - | - | - | -2.91 | -1.64 | -1.64 |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -2.91 | -1.64 | -1.64 |
| EBITDA | ||||||||||||
| EBITDA margin (%) | - | - | - |